MiNK Therapeutics, Inc.
INKTNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$12.6M | −$11.3M | −$22.9M | −$30.9M | −$28.4M | −$14.6M |
| Net income | −$12.5M | −$10.8M | −$22.5M | −$28.0M | −$30.2M | −$16.2M |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M | $4.6M |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$14.2M | −$19.6M | −$18.1M | −$401,303 | $23.8M | −$53.9M |
| EPS (diluted) | $-2.93 | $-2.86 | $-6.54 | $-0.83 | $-1.16 | — |
| Shares out. | 4.0M | 34.7M | 33.9M | 33.6M | 33.5M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 87.8%
- Return on assets
- −87.7%
- Return on capital (ROCE)
- −1047.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-3.59
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −46.1%clean
- Piotroski F-Score
- 4/6mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Negative shareholder equity
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ryan BarbaraDirector | Mar 9, 2026 | Sell | 200 | $10.17 |
| Ryan BarbaraDirector | Feb 27, 2026 | Sell | 400 | $10.86 |
| Buell JenniferOfficer — Chief Executive Officer | Jan 2, 2026 | Grant | 31,474 | $11.12 |
| Corvese BrianDirector | Dec 1, 2025 | Grant | 1,612 | $11.09 |
| Behner PeterDirector | Dec 1, 2025 | Grant | 1,466 | $11.09 |
| Ryan BarbaraDirector | Dec 1, 2025 | Grant | 1,601 | $11.09 |
| Holcomb John BradleyDirector | Dec 1, 2025 | Grant | 1,128 | $11.09 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 122,957 | 4.4 | +26.6% |
| Apr 30, 2026 | 97,106 | 1.7 | +0.6% |
| Apr 15, 2026 | 96,493 | 1.9 | -30.6% |
| Mar 31, 2026 | 139,115 | 1.8 | -7.1% |
| Mar 13, 2026 | 149,702 | 1.0 | +303.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 15, 2026
- Results of operationsMar 31, 2026
- Other material eventMar 27, 2026
- Director / officer changeMar 19, 2026
- Director / officer changeJan 2, 2026
- Results of operationsDec 8, 2025
- Director / officer changeSep 29, 2025
- Results of operationsAug 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.